Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Activated Charcoal on Mavacamten PK
NCT05320094Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the plasma concentration-time curve from time zero extrapolated to infinite time up to 2 months, Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration up to 2 months and 1 more. Started Apr 2022; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05320094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320094.